Table 1 Baseline characteristics and psychiatric morbidity

Age, mean (range)

58

(44–67)

Male sex, n (%)

9

(53)

BMI, mean (range)

27.2

(17.5–35.6)

HCV RNA IE/mL, median (range)

2.6 × 10⁶

(2.8 × 10⁵ - 16 × 10⁶)

 1a

7

(41)

 1b

3

(18)

 3a

5

(29)

 1a/1b/1×

2

(12)

 European

16

(94)

 Middle Eastern

1

(6)

Previous IFN treatment, n (%)

11

(65)

 Psychiatric side effects during IFN treatment, n

6

Liver cirrhosis, n (%)

10

(59)

 Child-Pugh A

9

 Child-Pugh B

1

Current psychiatric morbidity, n (%)

6

(35)

 Any mood disorder

4

(24)

 Any substance abuse or dependence^a

2

(12)

 Any anxiety disorder

1

(6)

 ADHD^c

2

(12)

Lifetime psychiatric morbidity, n (%)

15

(88)

 Any mood disorder

10

(59)

 Any psychotic disorder^b

1

(6)

 Any substance abuse or dependence

11

(65)

 Any anxiety disorder

6

(35)

 Any eating disorder

2

(12)

 ADHD^c

2

(12)

 Any psychotropic medication

8

(47)

 Antidepressants

3

(18)

 Benzodiazepines

3

(18)

 Benzodiazepine-like agents for sleep

3

(18)

 Central nervous system stimulants

1

(6)

 Buprenorphine

2

(12)